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E-mail address: ELIO.LIBOI@UNIVR.IT (E. Liboi).The kinase activity of the thanatophoric dysplasia type II–ﬁbroblast growth factor receptor 3 mutant
(TDII–FGFR3) hampers its maturation. As a consequence, the immature receptor activates extracel-
lular regulated kinases (ERKs) from the endoplasmic reticulum (ER), which leads to apoptosis. On
the other hand, in stable TDII–FGFR3 cells receptor biosynthesis is restored and ERKs are activated
from the cell surface. To identify potential mediators of cell adaptation to the activated receptor we
investigated gene products that are differently regulated in TDII and wild-type FGFR3 cells. cDNA
representational difference analysis reveals Sprouty4 up regulation in the TDII–FGFR3 cells. Interest-
ingly, Sprouty4 inhibits the TDII–FGFR3-mediated ERKs activation from the ER, but fails to suppress
ERKs activation from cell surface. We conclude that cell adaptation to activated FGFR3 include Spro-
uty4 activity, which silences the premature receptor signaling and suppress apoptosis.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Fibroblast growth factor receptor 3 (FGFR3) is a member of the
tyrosine kinase FGFR family [1] and plays an important role in a
variety of processes of embryonic development and tissue homeo-
stasis [2,3]. Mutations in the kinase activation loop domain of the
FGFR3 are associated to bone disorders and cancer [4], diseases
with opposite patho-physiological proﬁles. We have previously
shown that the kinase activity associated to the K650E substitu-
tion of the thanatophoric dysplasia type II (TDII)–FGFR3 affects
receptor trafﬁcking and results both in the accumulation of the
immature 120 kDa TDII glycomer in the endoplasmic reticulum
(ER) and apoptosis [5,6]. Accordingly, apoptosis has been detected
in chondrocytes from TD fetuses in vivo and in the ATDC5 chon-
drogenic line in vitro [7,8]. On the contrary, enlarged brains with
increased proliferation and decreased apoptosis of the cortical
progenitors it was shown in mice carrying the FGFR3 with thechemical Societies. Published by E
ceptor 3; TDII, thanatophoric
al difference analysis; ERK,
ulumK644E mutation [9] indicating how the cellular environment
may affect FGFR3 behavior. Furthermore, we have recently shown
that, in transient expression assays, the immature TDII receptor
glycomers transduce the signal from the ER thus leading to the
activation of the extracellular regulated kinase (ERK) proteins
through FRS2a and PLC-gamma independent pathways [10]. Dif-
ferently, in stable cell lines where both immature and mature
FGFR3 phosphorylated glycomers are detected, ERKs are activated
from the cell surface through the canonical FRS2a/Grb2/Ras/
MAPK pathway [3,10].
The ﬁrst Sprouty gene was identiﬁed in mutational screening
for genes that modulate FGF signaling during tracheal and eye
development in Drosophila [11]. Furthermore, Sprouty was found
to be a ligand-inducible antagonist of receptor tyrosine kinase
(RTK) signaling in Drosophila by its ability to suppress Ras/MAPK
pathway [12]. Four mammalian genes (Spry 1-4) encoding pro-
teins that share a highly conserved cystein-rich domain at the
carboxyl terminus that allow their inhibitory role on MAPK path-
way have been identiﬁed [13]. Expression of Sprouty4 is induced
by FGF signaling and it has been proposed that Sprouty4 protein
functions as FGF-induced feedback inhibitor [14]. Furthermore,
Sprouty2 and Sprouty4 are essential for embryonic morphogene-
sis and regulation of FGF signaling [15]. It has been reported that
Sprouty2 disturbs FGFR3 degradation in the TDII conditionlsevier B.V. All rights reserved.
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FGFR3-mediated skeletal dysplasias [16]. In addition, it was
shown that Sprouty4 suppresses vascular epithelial growth factor
(VEGF)-induced Ras-independent activation of Raf1 by direct
binding to Raf1 through its carboxyl-terminal cystein-rich domain
[17].
In this study, we have investigated on genes that were differ-
ently regulated in TDII versus wild-type FGFR3 stable cell clones.
We ﬁnd that Sprouty4 is up regulated exclusively in the TDII–
FGFR3 cells and it inhibits the TDII-induced ERKs activation from
the ER. We suggest a role by Sprouty4 in the adaptation process
to the activated FGFR3.2. Materials and methods
2.1. Cells and transfection
Hek239 cells-derived FGFR3 cell clones were generated as pre-
viously described [5]. Transfections were performed with Lipofect-
amine-2000 (Invitrogen) as described [5,6]. FGFR3 constructs were
previously described [5,6].
2.2. cDNA representational difference analysis (cDNA-RDA)
cDNA-RDA was originally described by Hubank and Shatz [18].
Brieﬂy: polyA+ RNA was obtained from HEK293 cells, two indepen-
dent HEK293-derived TDII–FGFR3 clones (TDII cl. 77 and 55), two
independent wild-type FGFR3 clones (wt clones 3 and 15) and
one G418-resistant HEK293 cell clone. The ﬁrst-strand cDNA was
synthesized by SuperScript (Invitrogen). The second-strand cDNA
was synthesized in RT2 buffer, bNAD, Escherichia coli DNA ligase,
E. coli DNA polymerase, dNTP’s and incubated for 2 h at 15 C
and then for 1 h at 22 C. Double stranded (ds) cDNA was digested
with Dpn II at 37 C for 1.5 h. The R-24mer and R-12mer linkers (R-
24mer 50-AGCACTCTCCAGCCTCTCACCGCA-30; R-12mer 50-GAT-
CTGCGGTGA-30) were legated/annealed to the Dpn II restricted ds
cDNA’s. PCR was performed in PCR machine (Biometra). To gener-
ate ‘‘representations”, 200 ll PCR reactions were set up for each
representation. 40 lg of each representation were digested with
Dpn II to originate the cut ‘‘drivers” representations. ‘‘Tester” was
prepared by purifying 20 lg digested representation on a 1.2%
TBE gel. J-24mer and J-12mer oligos (J-24mer 50-ACCGACGTC-
GACTATCCATGAACA-30; J-12mer 50-GATCTGTTCATG-30) were
ligated to 2 lg of puriﬁed ‘‘tester” DNA. PCR was performed over-
night. Subtractive hybridization was performed by mixing 40 lg
of ‘‘driver” to 0.4 lg of J-ligated ‘‘tester” and extracted with phenol
chloroform. For each subtraction, 4 PCR reactions were performed
using 20 ll of subtractive hybridization. The ﬁrst difference prod-
uct was obtained by digesting 20 ll of the PCR products with Mung
Bean nuclease at 30 C for 35 min followed by 4 PCR reactions
using 20 ll of DNA as template with J-24mer primer. The ﬁrst dif-
ference product was digested with Dpn II to remove the J oligos.
For the second and third subtractive hybridization, 50 ng of N-oli-
gos were used (N-24mer 50-AGGCAACTGTGCTATCCGAGGGAA-30;
N-12mer 50- GATCTTCCCTCG-30). The subtractive and ampliﬁcation
steps were performed as above.
2.3. Sprouty4 cDNA cloning
Sprouty4 was cloned by PCR from HEK293–FGFR3–TDII cl. 77
cells using the following DNA primers: 50-ACAAAGCTTATGCTT-
GTGACCCTGCAGC-30 and 50-ACATCTAGATAAAACCTCTGACCTTGC-
30. The 1078 bp PCR product was cloned into PCRII topo vector
(Invitrogen) and transfected into DH5a competent cells. A Myc
tag was added in frame to the 30 end of Sprouty4 cDNA.2.4. Real time PCR
The level of Sprouty4 mRNA was measured by real-time quan-
titative RT-PCR (Life Technologies) using the PE ABI PRISM 7700
Sequence Detection System (Applied Biosystems). Expression of
the housekeeping gene GAPDH was measured in parallel as an
endogenous control. The sequences of forward and reverse primers
and of the TaqMan ﬂuorogenic probes, as designed by the Primer
Express 1.5 software, were Sprouty4 (GenBank No. NM030964):
forward 50-ACCTGCCCCGGCTTCA-30, reverse 50-AGGTCCTGGACTG-
TACGGAGAA-30, probe 50-FAM-CAGCTCCTCAAAGGCCCCTAGAAG-
CC-TAMRA-30; GAPDH (GenBank No. NM008084): forward 50-
TGTGTCCGTCGTGGATCTG-30, reverse 50-GATGCCTGCTTCACCACCT-
T-30, probe 50-TET-TGATGTCATCATACTTGGCAGGTTTCTCCA-TAM-
RA-30.
The probes were located at the junction between two exons.
Relative transcript levels were determined from the relative stan-
dard curve constructed from stock cDNA dilutions and divided by
the target quantity of the calibrator according to the manufac-
turer’s instructions.
2.5. Immunoblot and antibodies
Transfected cells were lysed in RIPA buffer (50 mM Tris–HCl, pH
8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS) in the presence of a mixture of protease and phosphatase
inhibitors, clariﬁed by centrifugation and subjected to immuno-
blot; FGFR3 proteins were resolved on 7% tricine gels as previously
described [10]. The following antibodies were used: anti-HA and
anti-Myc (Roche); anti-Phospho tyrosine 4G10 (UpState). Sprouty4
antibody was kindly provided by Dr. Akihiko Yoshimura (Kyushu
University). Goat anti-Sprouty4 antibody (L-17) was purchased
from Santa Cruz. Antibodies detecting ERKs (C-14) from Santa
Cruz; phospho-ERKs (Biosource); anti-GFP (Abcam), anti-tubulin
(Sigma). Immunoprecipitation (IP), and whole cell extracts (WCE)
were performed as previously described [5].3. Results and discussion
The incomplete maturation of the FGFR3 bearing the highly
activating K650E mutation (TDII mutation) is associated to the pre-
mature signaling from the ER by the immature 120-kDa receptor
glycomers. Furthermore, the premature signaling from the ER is
associated to apoptosis [5]. Accordingly, efforts to obtain stable cell
lines expressing the TDII–FGFR3 gave only a limited number of po-
sitive cell clones. On the contrary, cell lines expressing the wild-
type FGFR3 were easily achieved suggesting that the selection pro-
cess ending in cell adaptation to the activated TDII–FGFR3 required
further steps.
To identify potential mediators of the cell adaptation to the acti-
vated TDII–FGFR3, we have performed the PCR-coupled subtractive
process of representational difference analysis (RDA) on the
HEK293-derived TDII and wild-type FGFR3 cell clones. Further-
more, to rule out that any difference in gene regulation could be
the result of the G418-selection process, the cDNA-RDA was per-
formed on HEK293 cells that express the G418 resistance only.
After three rounds of subtractive hybridization/ampliﬁcation, we
have obtained the partial DNA sequences of gene products that
were differently regulated in the analyzed cell lines. Search
through BLAST database allowed us to identify a number of genes
that were differentially expressed in the TDII versus the wild-type
FGFR3 cells (the identiﬁed genes are listed in Table 1). Among
these products, Sprouty4 resulted up regulated in the TDII cells.
We have focused our attention on Sprouty4 because of its role as
a feedback-induced antagonist of FGF signaling in zebraﬁsh during
Table 1
Genes that are differentially expressed in stable TDII–FGFR3 versus wild-type FGFR3
cells.
Accession
number
Up regulated genes
NM030964 Sprouty4
NM004078 Cystein and glycine rich protein; CRP-1
NM001986 Ets variant gene 4; ETV-4
Down regulated genes
BC036472 Protein kinase beta-1 PKC beta 1
NM013906 A disentegrin-like and metalloprotease (reprolysin type) with
thrombospondin type 1 motif; ADAMTS-1
U52219 Melatonin related receptor; GPR50
NM021988 Zinc ﬁnger protein 6; ZNF6
M86181 Human prosaposin; hPSAP
BC0003322 Ubiquitin carboxyl-terminal esterase UCHL1
U19720 Reduced folate carrier L1; RFC/SLC19A1
Fig. 2. Sprouty4 protein level. TDII clone 77, wild-type clone 15 and mock HEK293
cells were immunoprecipitated with anti-Sprouty4 antibody (a generous gift by Dr.
Akihiko Yoshimura). As a positive control Sprouty4-Myc was independently
transfected into HEK293 cells and the Myc antibody used for immunoprecipitation.
Immunodetection was performed with Sprouty4 antibody. The same protein
extracts were immunoprecipitated and hybridized with anti-HA antibody to show
the 120 and 130 kDa FGFR3 forms in the cell clones.
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hypothesis that the signaling from the ER by the TDII variant
should be switched off to allow the TDII–FGFR3 cells selection,
Sprouty4 represented a reasonable candidate acting as inhibitor
of the TDII–FGFR3 intracellular signaling. The expression level for
the other members of the Sprouty family has not been examined.
The reason to ascribe Sprouty4 as a speciﬁc intracellular silencer
of the TDII signaling is because Sprouty4 suppresses the Ras-inde-
pendent ERKs activation but not the Ras-dependent ERKs activa-
tion [17]. To this regard, we have previously reported that the
TDII receptor activates ERKs from the ER through an FRS2a and
PLCc-independent pathway [10] therefore, the transduction path-
way from the ER is different from the one triggered by the mature
FGFR3 from the cell surface that include FRS2a/Grb2/Sos/Ras/Raf/
MAPK activation [3].
A ﬁrst series of experiments were aimed to conﬁrm the Sprou-
ty4 up regulation in the TDII–FGFR3 versus the wild-type cells. Ini-
tially, real time PCR was performed on TDII versus wild-type cells.
As shown in Fig. 1, a two- to threefold Sprouty4 increase was ob-
served in the TDII cells compared to the wild-type and the parental
G418-resistant HEK293 cells. The level of Sprouty4 in the TDII
clone 77 is slightly higher probably due to clonal variation. Fur-
thermore, to determine the Sprouty4 protein level in the TDII cells,
immunoprecipitation experiments were performed with Sprouty4
speciﬁc antibody. A faint band of approximately 35 kDa, indicating
the relatively low Sprouty4 endogenous level, was detected in the
TDII clone 77 (Fig. 2) as well as in two other independent TDIIFig. 1. Sprouty4 RNA expression levels in TDII versus wild-type FGFR3 cells. Real
time PCR shows Sprouty4 mRNA expression fold increase in untransfected-G418
resistant (mock), wt-FGFR3 clones 3 and 15, and TDII–FGFR3 clones 55 and 77 cells.clones analyzed (not shown). Sprouty4 protein remained unde-
tected in the wild-type FGFR3 as well as in the parental G418-
resistent HEK293 cells.
Next we examined whether in the stable TDII–FGFR3 cells the
ERKs were activated by the mature, fully glycosylated FGFR3 on
cell surface, or by the ER-located phosphorylated glycomers. For
the purpose, cells were treated with monensin, which is a drug
known to block the secretory pathway thus abolishing the pres-
ence of the receptors on the cell surface [6]. In Fig. 3A, we show
that monensin completely abolishes ERKs activation in the TDII
clone 77 (lane 5). To determine if the activated immature glycom-
ers, derived from FGFR3 with a different mutation, were signaling
as well from intracellular compartments, monensin treatment
were performed in the SADDAN-FGFR3 clone 3 (SADD cl. 3). The
SADDAN cells express a different, highly activated FGFR3 mutant,
who is associated to the severe achondroplasia with developmen-
tal delay and acanthosis nigricans (SADDAN, K650M substitution).
The result shown in Fig. 3A (lane 7) conﬁrms that the SADDAN-
FGFR3 behaves similarly to the TDII variant [10]. Furthermore, as
a control, we explored if monensin could affect both FGFR3 biosyn-
thesis and phosphorylation. For the purpose, the wild-type cl. 15,
TDII cl. 77 and SADDAN cl. 3 were treated with monesin. Fig. 3B
shows that neither FGFR3 biosynthesis nor phosphorylation are af-
fected by monensin treatment. Altogether these results indicate
that in the stable TDII/SADDAN cells the ERKs are activated from
the cell surface by the highly activated FGFR3 even if the immature
120 kDa phosphorylated glycomers are still present as shown in
Fig. 3B.
To investigate on the Sprouty4 functional role as a modulator of
the FGFR3 signaling, the Sprouty4 cDNA ampliﬁed by PCR from the
TDII clone 77 cDNA library, was obtained. Subsequently, the Myc
tag was inserted in frame to the 30 end of Sprouty4 and the expres-
sion vector named Sprouty4-Myc was generated to perform a ser-
ies of transfection experiments.
To determine if Sprouty4 could suppress ERKs activation by the
FGFR3 mutants from cell surface, Sprouty4-Myc was transfected
into the TDII and SADDAN cell clones. As predicted, Sprouty4
over-expression did not affect ERKs activation in both cell lines
(Fig. 4A) indicating that indeed, Sprouty4 cannot suppress the
Fig. 3. ERKs are activated from the cell surface by the TDII/SADDAN-FGFR3 in stable clones. (A) The parental HEK293, wild-type cl. 15, TDII cl. 77 and SADD cl. 3 cells were
analyzed for ERKs activation in the presence (+) or absence () of 3 lMmonensin for 5 h. Twenty micrograms of whole cell extracts were loaded in each lane and immunoblot
with anti-Ph-ERK antibody was performed. Filters were reprobed with the indicated antibody. (B) Neither FGFR3 biosynthesis nor phosphorylation are affected by monensin
treatment. The same cells as in (A) were treated with monensin for 5 hours. Cells exhibit both immature (120 kDa) and mature (130 kDa) glycomers as indicated. Only the
TDII and SADDAN cells exhibit both mature and immature phosphorylated glycomers.
Fig. 4. Sprouty4 does not suppress ERKs activation from cell surface. (A) TDII and SADDAN cell clones were transfected with Sprouty4 as indicated. ERKs activation remains
unchanged indicating that Sprouty4 does not affect the FGR3-mediated signal transduction from cell surface. (B) Parental HEK293 and the HEK293-derived Sprouty4 cells
were stimulated for 15 min with FGF1. Activated ERKs are detected upon FGF treatment in both cells. The data conﬁrms that the endogenous FGFR pathway is unaffected by
Sprouty4. (C) In the presence of Sprouty4, the wt cl. 15 cells still exhibit ERKs activation upon FGF1 treatment.
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Sprouty4 did not affect both TDII and SADDAN signaling from the
cell surface was obtained by analyzing FRS2a. Results showed that
FRS2a remained in its activated conformation in the presence of
Sprouty4 (not shown). Further experiments were performed to
investigate whether Sprouty4 could affect signaling by other
endogenous FGFR exposed on HEK293 cell surface. To this regard
it is worth mentioning that we did not detect endogenous FGFR3
in HEK293 cells [5]. Only low levels of endogenous FGFR2 were de-
tected in the HEK293 cells (unpublished observation) however, we
cannot exclude a low expression level of both FGFR1 and FGFR4.
For the purpose, HEK293 and the HEK293-derived Sprouty4 cells
(Sprouty4 cl. 4) were stimulated with FGF1 and the ERKs were ana-
lyzed. In Fig. 4B it is shown that ERKs are activated upon FGF1
stimulation even in the presence of Sprouty4. These data conﬁrm
that the FGFR-mediated signaling from cell surface is unaffected
by Sprouty4. Furthermore, the FGFR3 protein remains undetected
in the Sprouty4 cell line indicating that Sprouty4 does not up-reg-
ulate FGFR3 expression. In addition, we show that Sprouty4 does
not inhibit ERKs activation by FGF1 in the wt-FGFR3 cells thus con-
ﬁrming that Sprouty4 cannot abrogate the FGFR3-mediated signal-
ing from the cell surface (Fig. 4C).
Considering that Sprouty4 suppresses ERKs activation in the
Ras-independent pathway [17], we have investigated on whether
Sprouty4 could inhibit the ERKs activation triggered by the imma-
ture TDII and SADDAN receptors, in transient transfection assays.
For this purpose, Sprouty4 and the TDII or the SADDAN variants
were co-transfected and proteins were analyzed 48 h later.
Fig. 5A shows that Sprouty4 inhibits ERKs activation triggered by
both the TDII and the SADDAN receptors (lanes 3 and 4). Further-
more, the phosphorylation level of the TDII receptor (and SADDANreceptor, not shown) remains unchanged in the presence of Spro-
uty4 (Fig. 5B) indicating that Sprouty4 operates downstream the
Tyrosine phosphorylation event.
All together our data suggest that a physiological role played by
Sprouty4 could be to inhibit the signaling from the ER during the
cell adaptation process to activated TDII/SADDAN-FGFR3. We have
previously shown that the premature signaling from the ER by the
activated FGFR3 triggers an apoptotic response, which could be
consequent to a stress of the ER. We propose that suppression of
apoptosis is required to allow the positive selection of TDII/SAD-
DAN cell clones, a process that results from both adaptations to
activated FGFR3 and resistance to G418. The potential relevance
of cell adaptation to activated FGFR3 could be related to the path-
ogenesis of the FGFR3-related human cancers, as suggested by our
previous observation that the KMS11 and OPM-2 multiple myelo-
ma cells, although presenting a strong FGFR3 auto phosphoryla-
tion, fail to activate proteins (STATs) that are indeed activated by
the immature TDII–FGFR3, in transient expression, from intracellu-
lar compartments [5].
It remains to determine whether inhibition of Sprouty4 could re
establish the apoptotic pathway in stable TDII cells. A partial an-
swer derives from the observation that transfection of TDII–FGFR3
in stable TDII cell clone does not allow ERKs activation in the pres-
ence of monensin and apoptosis is undetected (not shown) thus
suggesting the irreversibility of the adaptation process. However,
more experiments such as Sprouty4 knockdown are required to
determine the precise role by Sprouty4 on cell adaptation to acti-
vated FGFR3.
In conclusion, Sprouty4 up-regulation may be initially triggered
by the activated FGFR3. Subsequently, Sprouty4 acting as a feed-
back inhibitor suppresses the signaling from the ER. Such a model
Fig. 5. ERKs activation from the ER by TDII–FGFR3 is abolished in the presence of Sprouty4. (A) Co-transfection of TDII–FGFR3 with Sprouty4-Myc followed by immunoblot
(IB) with the indicated antibody shows that ERKs activation by TDII and SADDAN-FGFR3 is drastically reduced in the presence of Sprouty4 (lanes 3 and 4). Sprouty4 alone
does not induce ERKs activation (lane 1). (B) Sprouty4 does not co-precipitate (top) with FGFR3–TDII and is not phosphorylated (bottom) by the FGFR3–TDII.
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TDII/SADDAN-FGFR3, in line with the report by Thomson et al.
[9] in which it is shown the increased Sprouty levels associated
to increased proliferation and decreased apoptosis of cortical pro-
genitors of K644E mice.
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